Embedded Files
23. “Exploration of Tetrahydroisoquinoline- and Benzo[c]azepine-Based Sphingosine 1-Phosphate Receptor 1 Agonists for the Treatment of Multiple Sclerosis,” Cha, E.; Kim, J.; Gotina, L.; Kim, J.; Kim, H. J.; Seo, S. H.; Park, J. -E.; Joo, J.; Kang, M.; Lee, J.; Hwang, H.; Kim, H. J.; Pae, A. N.*; Park, K. D.*; Park, J.-H.*; Lim, S. M.* J. Med. Chem. 2023, 66, 10381-10412.
22. “Levosimendan inhibits disulfide tau oligomerization and ameliorates tau pathology in TauP301LBiFC mice,” Lim, S.; Shin, S.; Sung, Y.; Lee, H. E.; Kim, K. Y.; Song, J. Y.; Lee, G.-H.; Aziz, H.; Lukianenko, N.; Kang, D. M.; Boesen, N.; Jeong, H.; Abdildinova, A.; Lee, J.; Yu, B.-Y.; Lim, S. M.; Lee, J.-S.; Ryu, H.; Pae, A. N.*; Kim, Y. K.* Exp. Mol. Med. 2023, 55, 612-627.
21. “Structural hybridization for inhibitors of the interaction between NRF2 and Keap1,” Lee, D. H.; Seo, S. H.; Gotina, L.; Pae, A. N.; Lim, S. M.* Bull. Kor. Chem. Sci. 2022, 43, 1088-1092.
20. “CHIP-mediated hyperubiquitylation of tau promotes its self-assembly into the insoluble tau filaments,” Kim, J. H.; Lee, J.; Choi, W. H.; Park, S.; Park, S. H.; Lee, J. H.; Lim, S. M.; Mun, J. Y.; Cho, H-. S.; Han, D.; Suh, Y. H.; Lee, M. J.* Chem. Sci. 2021, 12, 5599-5610.
19. “Pharmacophore-based virtual screening of novel competitive inhibitors of the neurodegenerative disease target kynurenine-3-monooxygenase. Gotina, L.; Seo, S. H.; Kim, C. W.; Lim, S. M.; Pae, A. N.* Molecules 2021, 26, 3314.
18. "Aggresomal sequestration and STUB1-mediated ubiquitylation during mammalian proteaphagy of inhibited proteasomes,” Choi, W. H.; Yun, Y.; Park, S.; Jeon, J. H.; Lee, J.; Lee, J. H.; Yang, S-. A.; Kim, N-. K.; Jung, C. H.; Kwon, Y. T.; Han, D.; Lim, S. M.; Lee, M. J.* Proc. Natl. Acad. Sci. USA 2020, 117, 19190-19200.
17. "Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model," Kim, S.; Viswanath, A. N. I.; Park, J-.H.; Lee, H. E.; Park, A. Y.; Choi, J. W.; Kim, H. J.; Londhe, A. M.; Jang, B. K.; Lee, J.; Hwang, H.; Lim, S. M.; Pae, A. N.*; Park, K. D.* Neuropharmacology 2020, 167, 107989.
16. “Evaluation of anti-depressant effects of phthalazinone-based triple-acting small molecules against 5-HT2A, 5-HT2C, and the serotonin transporter,” Kim, J.; Cha, E.; Park, W. K.; Lee, H. Y.; Lim, S. M.*; Kim, H. J.*; Pae, A. N.* Bioorg. Med. Chem. Lett. 2020, 30, 126882.
15. “Decoding principles of selective GPCR-Gα coupling,” Lim, S. M.* Biochemistry 2020, 59, 130-131.
14. “Metabolic engineering of Escherichia coli to produce a monophosphoryl lipid A adjuvant,” Ji, Y.; An, J.; Hwang, D.; Ha, D. H.; Lim, S. M.; Lee, C.; Zhao, J.; Song, H. K.; Yang, E. G.; Zhou, P.; Chung, H. S.* Metab. Eng. 2020, 57, 193-202.
13. “The recent pharmaceutical patent landscape for Alzheimer’s disease: an interview with Sang Min Lim,” Lim, S. M.* Pharm. Pat. Anal. 2019, 8, 215-216.
12. “Investigation of Molecular Details of Keap1-Nrf2 Inhibitors Using Molecular Dynamics and Umbrella Sampling Techniques,” Londhe, A. M.; Gadhe, C. G.; Lim, S. M.; Pae, A. N.* Molecules 2019, 24, 4085-4106.
11. “Recent tau-targeted clinical strategies for the treatment of Alzheimer’s disease,” Lee, H. E.; Lim, D.; Lee, J. Y.; Lim, S. M.*; Pae, A. N.* Future Med. Chem. 2019, 11, 1845-1848.
10. “Structural hybridization of pyrrolidine-based T-type calcium channel inhibitors and exploration of their analgesic effects in a neuropathic pain model,” Son, W. S.; Jeong, K. –S.; Lim, S. M.*; Pae, A. N.* Bioorg. Med. Chem. Lett. 2019, 29, 1186-1172.
9. “Development of tau-directed small molecule modulators for Alzheimer’s disease: a recent patent review (2014-2018),” Lee, H. E.; Lim, D.; Lee, J. Y.; Lim, S. M.*; Pae, A. N.* Pharm. Pat. Anal. 2019, 8, 15-39.
8. “Synthesis and biological evaluation of pyrrolidine-based T-type calcium channel inhibitors for the treatment of neuropathic pain,” Yang, H. K.; Son, W. S.; Lim, K. S.; Kim, G. H.; Lim, E. J.; Gadhe, C. G.; Lee, J. Y.; Jeong, K-.S.; Lim, S. M.*; Pae, A. N.* J. Enzyme Inhib. Med. Chem. 2018, 33, 1460-1471.
7. “Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease,” Lim, J. W.; Kim, S. K.; Choi, S. Y.; Kim, D. H.; Gadhe, C. G.; Lee, H. N.; Kim, H-.J.; Kim, J.; Cho, S. J.; Hwang, H.; Seong, J.; Jeong, K-.S.; Lee, J. Y.*; Lim, S. M.*; Lee, J. W.*; Pae, A. N.* Eur. J. Med. Chem. 2018, 157, 405-422.
6. “GRP78-targeted In-silico Virtual Screening of Novel Anticancer Agents,” Viswanath, A. N. I.; Lim, J. W.; Seo, S. H.; Lee, J. Y.; Lim, S. M.; Pae, A. N.* Chem. Biol. Drug Des. 2018, 92, 1555-1566.
5. “Ligand-controlled Regiodivergent C-H Alkenylation of Pyrazoles and its Application to the Synthesis of Indazoles,” Kim, H. T.; Ha, H.; Kang, G.; Kim, O. S.; Ryu, H.; Biswas, A. K.; Lim, S. M.*; Paik, M.-H.*; Joo, J. M.* Angew. Chem., Int. Ed. 2017, 56, 16262-16266.
4. “In Silico‐designed Novel non‐Peptidic ABAD LD Hot Spot Mimetics Reverse Aβ‐induced Mitochondrial Impairments in vitro,” Viswanath, A. N. I.; Kim, T. H.; Jung, S. Y.; Lim, S. M.; Pae, A. N.* Chem. Biol. Drug Des. 2017, 90, 1041-1055.
3. “Discovery of Thienopyrrolotriazine Derivatives to Protect Mitochondrial Function against Aβ-induced Neurotoxicity,” Kim, T. H.; Son, W. S.; Morshed, M. N.; Londhe, A. M.; Jung. S. Y.; Park, J.-H.; Park, W.-K.; Lim, S. M.; Park, K. D.; Cho, S. J.; Jeong, K.-S.; Lee, J.*; Pae, A. N.* Eur. J. Med. Chem. 2017, 141, 240-256.
2. “Discovery of non-Peptidic Small Molecule Inhibitors of Cyclophilin D as Neuroprotective Agents in Aβ-induced Mitochondrial Dysfunction,” Park, I.; Londhe, A. M.; Lim, J. W.; Park, B.-G.; Jung, S. Y.; Lee, J. Y.; Lim, S. M.; No, K. T.; Lee, J.; Pae, A. N.* J. Comput. Aided Mol. Des. 2017, 31, 929-941.
1. “Identification of the First In Silico-designed TREK1 Antagonists that Block Channel Currents Dose-dependently,” Viswanath, A. N. I.; Jung, S. Y.; Hwang, E. M.; Park, K. D.; Lim, S. M.; Min, S.-J.; Cho, Y. S.; Pae, A. N.* Chem. Biol. Drug Des. 2016, 88, 807-819.
Before KIST
17. “Small Molecule Selectively Suppresses MYC Transcription in Cancer Cells,” Bouvard, C.; Lim, S. M.; Ludka, J.; Yazdani, N.; Woods, A. K.; Chatterjee, A. K.; Schultz, P. G.*; Zhu, S. Proc. Natl. Acad. Sci. USA 2017, 114, 3497-3502.
16. “Covalent Guanosine Mimetic Inhibitors of G12C KRAS,” Xiong, Y.; Lu, J.; Hunter, J.; Li, L.; Scott, D.; Choi, H. G.; Lim, S. M.; Manandhar, A.; Gondi, S.; Sim, T.; Westover, K. D.; Gray, N. S.* ACS. Med. Chem. Lett. 2017, 8, 61-66.
15. “Optimization and Biological Evaluation of Aminopyrimidine-based IkB Kinase β Inhibitors with Potent Anti-inflammatory Effects,” Shin, Y.; Lim, S. M. (co-first author); Yan, H. H.; Jung, S.; Fang, Z.; Jung, K. H.; Hong, S.-S.*; Hong, S.* Eur. J. Med. Chem. 2016, 123, 544-556.
14. “Strategies to Overcome Acquired Resistances Conferred by Mutations in the Kinase Domain of EGFR,” Lim, S. M.; Jeong, Y.; Hong, S.* Future Med. Chem. 2016, 8, 853-878.
13. “Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors to Treat an Aggressive Subtype of Diffuse Large B-cell Lymphoma,” Lim, S. M.; Jeong, Y.; Lee, S.; Im, H.; Tae, H. S.; Kim, B. G.; Park, H. D.; Park, J.*; Hong, S.* J. Med. Chem. 2015, 58, 8491-8502.
12. “Discovery of Wrightiadione as a Novel Template for the TrkA Kinase Inhibitors,” Jeong, Y.; Lim, S. M.; Hong, S.* Bioorg. Med. Chem. Lett. 2015, 25, 5186-5189.
11. “Development of Small Molecules Targeting the Pseudokinase Her3,” Lim, S. M.; Xie, T.; Westover, K. D.; Ficarro, S. B.; Tae, H. S.; Gurbani, D.; Sim, T.; Marto, J. A.; Jänne, P. A.; Crews, C. M.; Gray, N. S.* Bioorg. Med. Chem. Lett. 2015, 25, 3382-3389.
10. “Pharmacological Targeting of the Pseudokinase Her3,” Xie, T.; Lim, S. M.; Westover, K. D.; Dodge, M. E.; Ercan, D.; Ficarro, S. B.; Udayakumar, D.; Tae, H. S.; Riddle, S. M.; Sim, T.; Marto, J. A.; Jänne, P. A.; Crews, C. M.; Gray, N. S.* Nat. Chem. Biol. 2014, 10, 1006-1012.
Highlighted in Chemical & Engineering News “Troublemaking HER3 Enzyme Trashed,” Borman, S. 2014, 92, 8.;
Highlighted in Science-Business eXchange (SciBX) Distillery: Therapeutics, 2014, 7(44); doi:10.1038/scibx.2014.1287.
9. “In situ Selectivity Profiling and Crystal Structure of SML-8-73-1, an Active Site Inhibitor of Oncogenic K-Ras G12C,” Hunter, J. C.; Gurbani, D.; Ficarro, S. B.; Carrasco, M. A.; Lim, S. M.; Choi, H. G.; Xie, T.; Marto, J. A.; Chen, Z.; Gray, N. S.; Westover, K. D.* Proc. Natl. Acad. Sci. USA 2014, 111, 8895-8900.
8. “Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor,” Lim, S. M.; Westover, K. D.; Ficarro, S. B.; Harrison, R. A.; Choi, H. G.; Pacold, M. E.; Carrasco, M.; Hunter, J.; Kim, N. D.; Xie, T.; Sim, T.; Jänne, P. A.; Meyerson, M.; Marto, J. A.; Engen, J.; Gray, N. S.* Angew. Chem. Int. Ed. 2014, 53, 199-204.
Highlighted in Science-Business eXchange (SciBX) “Covalent Hits on KRAS,” Donner, A. 2014, 7, 6-7.;
Highlighted in Angewandte Chemie International Edition “Selective Inhibition of Mutant Ras Protein through Covalent Binding,” Rudolph, J.; Stokoe, D. 2014, 53, 3777-3779.
7. “Leveraging Kinase Inhibitors to Develop Small Molecule Tools for Imaging Kinases by Fluorescence Microscopy,” Zhang, Z.; Kwiatkowski, N.; Zeng, H.; Lim, S. M.; Gray, N. S.; Zhang, W.; Yang, P. L.* Mol. BioSyst. 2012, 8, 2523-2526.
6. “Broad Spectrum Alkynyl Inhibitors of T315I Bcr-Abl,” Deng, X.; Lim, S. M.; Zhang, J.; Gray, N. S.* Bioorg. Med. Chem. Lett. 2010, 20, 4196-4200.
5. “A Method for the Preparation of Differentiated trans-1,2-Diol Derivatives with Enantio– and Diastereocontrol,” Lim, S. M.; Hill, N.; Myers, A. G.* J. Am. Chem. Soc. 2009, 131, 5763-5765.
4. “Stereoselective Synthesis of (+)−IKD−8344,” Kim, W. H.; Hong, S. K.; Lim, S. M.; Ju, M.-A.; Jung, S. K.; Kim, Y. W.; Jung, J. H.; Kwon, M. S.; Lee, E.* Tetrahedron 2007, 63, 9784-9801.
3. “Total Synthesis of IKD−8344,” Kim, W. H.; Hong, S. K.; Lim, S. M.; Ju, M.-A.; Jung, S. K.; Kim, Y. W.; Jung, J. H.; Kwon, M. S.; Lee, E.* Angew. Chem., Int. Ed. 2006, 45, 7072-7075.
2. “Synthesis of the Proposed Structure of Feigrisolide C,” Kim, W. H.; Jung, J. H.; Sung, L. T.; Lim, S. M.; Lee, E.* Org. Lett. 2005, 7, 1085-1087.
1. “Total Synthesis of Ambruticin,” Lee, E.; Choi, S. J.; Kim, H.; Han, H. O.; Kim, Y. K.; Min, S. J.; Son, S. H.; Lim, S. M.; Jang, W. S. Angew. Chem., Int. Ed. 2002, 41, 176-178.
Page updated
Google Sites
Report abuse